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ApoptosisAbstract A series of cinnamido-propionone conjugates (4–6a-h and 7a-f) has been designed, syn-
thesized and evaluated for their anticancer potential against some human cancer cell lines. Among
them, conjugates 6d and 6g have shown significant cytotoxic activity against prostate cancer cells
(DU-145) displaying IC50 of 7.48 and 8.91 lM respectively. Studies to understand the mechanism
of action of 6d and 6g indicate that they inhibit the tubulin polymerization thereby arresting the
cell cycle in G2/M phase. Furthermore, studies such as mitochondrial membrane potential and
Annexin V-FITC assay suggested that these conjugates 6d and 6g induced cell death by apoptosis.
The molecular docking studies suggested that the binding by these conjugates takes place at the col-
chicine site of the tubulin protein.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
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Among the current targets for cancer chemotherapy, along-side DNA,
microtubules play a critical role (Ducki et al., 2015; Jordan et al.,
1998). Microtubules are of particular importance for the formation
of the mitotic spindle, which provides the structural framework forthe physical segregation of chromosomes during cell division (mitosis)
(Desai and Mitchison, 1997; Hyams and Lloyd, 1994; Hadfield et al.,
2003). They are crucial in a number of cellular functions, such as cell
growth, chromosome segregation during cell division, formation and
maintenance of cell shape, regulation of motility, cell signalling and
intracellular transport (Amos, 2004; Downing and Nogales, 1998).
Microtubules are large, dynamic cylindrical protein copolymers con-
sisting of alternating a and b tubulin heterodimers. Drugs that disrupt
microtubule/tubulin dynamics are used widely in cancer chemotherapy
interfering with the dynamic instability of microtubules and thereby
disrupting microtubules, inducing cell cycle arrest in the M-phase,
resulting in the apoptotic cell death (Pasquier et al., 2007). Well known
examples include taxanes (such as paclitaxel and docetaxel), that stabi-
lize microtubule by binding to the btubulin subunit (Snyder et al.,
2001), whereas vinca alkaloids of natural origin and colchicine (1), that
bind to a different site of b-tubulin and inhibits its assembly into
microtubules (Uppuluri et al., 1993). Nocodazole (2) is another well-Arabian
2 N. Sankara Rao et al.known inhibitor of tubulin polymerization which inhibits cell prolifer-
ation and largely used for pharmacological tool and positive control
(Duanmu et al., 1989; Vasquez et al., 1997). Emerging evidence reveals
that targeting tubulin is a promising approach for cancer chemother-
apy. However, most of the tubulin-binding agents are derived from
natural products with complex chemical structures that restrict chem-
ical modification. Therefore, active compounds with relatively simple
chemical structures could be valuable candidates for further
development.
Therefore, there is a growing interest in identifying and developing
newer molecules that could inhibit tubulin polymerization. Cinnamides
are another class of anticancer agents, and its natural analogues are
known for the treatment of cancer for over centuries. Phenylcin-
namides are shown to bind to tubulin, thereby causing an inhibition
of its polymerization and alteration in the tubulin-microtubule equilib-
rium. They are known to possess an a,b-unsaturated carbonyl moiety,
which can be considered as a Michael acceptor, employed as a power-
ful tool in the design of antimitotic agents and its ability to interact
with cellular nucleophiles, particularly to the glutathione (GSH) and
cystine residues (Carolin et al., 2014). Hergenrother and co-workers
synthesized several phenylcinnamide derivatives to study their
structure-activity relationship (SAR) and among them, compound 3
(8H) showed significant activity (Leslie et al., 2010). These compounds
induce M-phase of the cell cycle arrest leading to cell death and disrup-
tion of microtubule dynamics. Our recent research studies have been
mainly focused on the synthesis, evaluation and mechanistic aspects
of newer molecules based on different heterocyclic scaffolds as poten-
tial anticancer agents (Kamal et al., 2011, 2012) particularly, tubulin
targeting compounds. Some of the potent hybrid/conjugate molecules
that have been recently developed as new anticancer agents are
obtained by the combination of different pharmacophores (Bonne
et al., 1985; Huber et al., 2008). Structural features of designed mole-
cules, including the trimethoxyphenyl moiety (found in colchicine and
8H), suggested that these molecules exerted cytotoxic action through
microtubule binding and mitotic arrest. Based on these observations,
we here in describe modifications on 8H scaffold by conjugating with
substituted arylpropynones to the cinnamide moiety. In this context,
we have designed and synthesized some newer cinnamido-
propionone conjugates and evaluated them for their cytotoxic poten-
tial apart from their effect on the inhibition of tubulin polymerization.
2. Material and methods
1H NMR spectra were recorded on Avance 300, Inova 400,
Avance 500, and Bruker 600 MHz spectrometers using tetram-
ethyl silane (TMS) as the internal standard. Chemical shifts are
reported in parts per million (ppm) downfield from tetramethyl
silane. Spin multiplicities are described as s (singlet), brs
(broad singlet), d (doublet), dd (double doublet), t (triplet), q
(quartet), and/or m (multiplet). Coupling constants are
reported in Hertz (Hz). Melting points were determined in a
capillary tube using an Electrothermal apparatus (Model
IA9200) and are uncorrected. The IR spectra were recorded
by employing a Nicolet FTIR model MX-1 spectrophotome-
ter. Analytical thin layer chromatography (TLC) was per-
formed on MERCK precoated silica gel 60-F254 (0.5-mm)
glass plates. Visualization of the spots on TLC plates was
achieved either by exposure to iodine vapour or UV light or
by dipping the plates into methanolic sulphuric acid-b-
naphthol or to ethanolic anisaldehyde-sulphuric acid-acetic
acid or to ethanolic ninhydrin solution and heating the plates
to 120 C. Column chromatography was performed using sil-
ica gel 60–120 and 100–200 mesh. Moisture sensitive reactions
were carried out using standard syringe septum Techniques
and under inert atmosphere of nitrogen. All solvents andPlease cite this article in press as: Sankara Rao, N. et al., Arylcinnamido-propionone
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of solvents was carried out under reduced pressure on
Laborota-4000 rotary evaporator below 45 C. The names of
all the compounds given in the experimental section were taken
from Chem Ultra, Version 11.0.
2.1. General method for the synthesis of substituted nitro
phenylcinnamides (9a-b and 15a-b)
To the ice cold solution of cinnamic acids (1 mmol) in dry
dichloromethane added the oxalyl chloride (3 mmol) and a cat-
alytic amount of N,N-dimethyl formamide (1 mol%) and stir-
red for 3 h at room temperature after completion of reaction
and also excess of solvent and oxalyl chloride was removed
under reduced pressure to give respected acid chlorides. These
were dissolved in dry tetrahydrofuran and added to stock solu-
tions of 3,4,5-trimethoxy anilines (0.9 mmol) and triethylamine
(3 mmol) in dry tetrahydrofuran at 0 C and stirred for 12 h at
room temperature after completion of reaction and the reac-
tion mixture was diluted with ethyl acetate, washed with water
and brine solution, dried over sodium sulphate and purified by
column chromatography using ethyl acetate and hexane as
elutents.
2.1.1. (E)-3-(4-Methoxy-3-nitrophenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (9a)
The compound 9a was prepared according to the general
method, employing (E)-3-(4-methoxy-3-nitrophenyl)acrylic
acid 8a, 500 mg, (2.24 mmol) and 3,4,5-trimethoxyaniline
(450 mg, 2.46 mmol) to obtain the pure product 9a as a pale
yellow solid. Yield 69%; m.p: 198 C; 1H NMR (300 MHz,
CDCl3) d (ppm): 8.04 (s, 1H), 7.71–7.62 (m, 2H), 7.56 (s,
1H), 7.11 (d, J= 9.0 Hz, 1H), 6.98 (s, 2H), 6.52 (d,
J= 15.1 Hz, 1H), 4.00 (s, 3H), 3.86 (s, 6H), 3.83 (s, 3H);
MS (ESI, m/z): 389 [M+H]+.
2.1.2. (E)-3-(3,4-Dimethoxy-5-nitrophenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (9b)
The compound 9b was prepared according to the general
method, employing (E)-3-(3,4-dimethoxy-5-nitrophenyl)acrylic
acid 8b 500 mg, (1.98 mmol) and 3,4,5-trimethoxyaniline
(398 mg, 2.17 mmol) to obtain the pure product 9b as a pale
yellow solid. Yield 71%; m.p: 212 C; 1H NMR (300 MHz,
CDCl3 + DMSO) d 9.63 (s, 1H), 7.65–7.54 (m, 2H), 7.46 (s,
1H), 7.09 (s, 2H), 6.81 (d, J= 15.6 Hz, 1H), 4.04–3.96 (m,
6H), 3.91–3.85 (m, 6H), 3.84–3.79 (m, 3H); MS (ESI, m/z):
419 [M+H]+.
2.1.3. (E)-3-(3-(Allyloxy)-4-nitrophenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (15a)
The compound 15a was prepared according to the general
method, employing (E)-3-(3-(allyloxy)-4-nitrophenyl)acrylic
acid 14a, 500 mg, (2.01 mmol) and 3,4,5-trimethoxyaniline
(404 mg, 2.21 mmol) to obtain the pure product 15a as a pale
yellow solid. Yield 68%; m.p: 241 C; 1H NMR (300 MHz,
CDCl3) d (ppm): 7.88 (d, J= 8.3 Hz, 1H), 7.70–7.65 (m, 2H),
7.17–7.14 (m, 2H), 6.97 (s, 2H), 6.58 (d, J= 15.1 Hz, 1H),
6.11–5.97 (m, 1H), 5.49 (dd, J= 1.51 Hz, J= 17.3 Hz, 1H),
5.37 (dd, J= 1.51 Hz, J= 10.5 Hz, 1H), 4.70 (d, J= 5.2 Hz,
2H), 3.86 (s, 6H), 3.84 (s, 3H); MS (ESI, m/z): 415 [M+H]+.conjugates as tubulin polymerization inhibitors and apoptotic inducers. Arabian
Arylcinnamido-propionone conjugates as tubulin polymerization inhibitors and apoptotic inducers 32.1.4. (E)-3-(4-Nitro-3-(prop-2-ynyloxy)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (15b)
The compound 15b was prepared according to the general
method, employing (E)-3-(4-nitro-3-(prop-2-ynyloxy)phenyl)a
crylic acid 14b, 500 mg, (2.02 mmol) and 3,4,5-
trimethoxyaniline (406 mg, 2.22 mmol) to obtain the pure pro-
duct 15b as a pale yellow solid. Yield 70%; m.p: 237 C, 1H
NMR (300 MHz, CDCl3 + DMSO) d (ppm): 10.00 (s, 1H),
7.89 (d, J= 8.3 Hz, 1H), 7.62 (d, J= 15.4 Hz, 1H), 7.47 (s,
1H), 7.31 (d, J= 8.3 Hz, 1H), 7.11 (s, 2H), 6.92 (d,
J= 15.4 Hz, 1H), 4.96 (d, J= 2.2 Hz, 2H), 3.86 (s, 6H),
3.78 (s, 3H), 2.97 (t, J= 2.2 Hz, 1H); MS (ESI, m/z): 413
[M+H]+.
2.2. General method for the synthesis of substituted amino
phenylcinnamides (10a-b and 16a-b)
Compounds 9a, 9b and 15a, 15b (1 mmol) were dissolved in
methanol and added the zinc powder (3 mmol) and ammo-
nium formate (3 mmol) portion wise at 0 C and stirred at
room temperature for 12 h after completion of reaction, the
reaction mixture was filtered to remove the residual zinc, the
solvent was removed under reduced pressure, the residue was
dissolved in ethyl acetate and washed with water and brine
solution and dried over sodium sulphate and solvent was
removed under reduced pressure and purified by column chro-
matography using ethyl acetate and hexane as eluents.
2.2.1. (E)-3-(3-Amino-4-methoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (10a)
The compound 10a was prepared according to the general
method, employing (E)-3-(4-methoxy-3-nitrophenyl)-N-(3,4,5-
trimethoxyphenyl) acryl amide. 600 mg, (1.55 mmol) to obtain
the pure product 10a as a pale yellow solid. Yield 65%; m.p:
126 C; 1H NMR (500 MHz, CDCl3) d (ppm): 7.64 (d,
J= 15.4 Hz, 1H), 7.44 (bs, 1H), 6.96 (s, 2H), 6.93–6.86 (m,
2H), 6.78–6.75 (m, 1H), 6.33 (d, J= 15.4 Hz, 1H), 3.88 (s,
3H), 3.86 (s, 6H), 3.82 (s, 3H); 13C NMR (125 MHz, CDCl3)
d (ppm): 164.7, 153.2, 149.0, 142.5, 136.4, 134.5, 134.4,
127.5, 119.9, 118.0, 112.9, 110.1, 97.5, 60.9, 55.9, 55.5; IR
(KBr) (mmax/cm
1): 3380, 3004, 2935, 2839, 1681, 1606, 1546,
1507, 1452, 1429, 1411, 1343, 1301, 1263, 1235, 1210, 1186,
1168, 1128, 1018, 994, 972, 925, 886, 849, 836, 801; MS (ESI,
m/z): 359 [M+H]+; HRMS (ESI m/z) Calculated for
C19H23O5N2: 359.1601, found: 359.1594 [M+H]
+.
2.2.2. (E)-3-(3-Amino-4,5-dimethoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (10b)
The compound 10b was prepared according to the general
method, employing (E)-3-(3,4-dimethoxy-5-nitrophenyl)-N-(3,
4,5-trimethoxyphenyl)acrylamide (600 mg, 1.44 mmol) to
obtain the pure product 10b pale yellow solid Yield 71%; m.
p: 191 C; 1H NMR (300 MHz, CDCl3) d (ppm): 8.76 (bs,
1H), 7.55 (d, J= 15.4 Hz, 1H), 7.05 (s, 2H), 6.57–6.50 (m,
3H), 3.98 (bs, 2H), 3.85–3.80 (m, 15H); 13C NMR (75 MHz,
CDCl3) d (ppm): 164.4, 153.0, 152.7, 141.7, 140.7, 137.1,
134.8, 134.2, 130.6, 120.1, 108.1, 101.9, 97.4, 60.7, 59.8, 55.8,
55.5; IR (KBr) (mmax/cm
1): 3467, 3346, 3299, 2938, 1672,
1612, 1583, 1542, 1505, 1449, 1428, 1412, 1323, 1297, 1282,
1235, 1205, 1187, 1128, 998, 977; MS (ESI, m/z): 389Please cite this article in press as: Sankara Rao, N. et al., Arylcinnamido-propionone
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389.1707, found: 389.1702 [M+H]+.
2.2.3. (E)-3-(3-(Allyloxy)-4-aminophenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (16a)
The compound 16a was prepared according to the general
method, (E)-3-(3-(allyloxy)-4-nitrophenyl)-N-(3,4,5-trimethox
yphenyl)acrylamide. 600 mg, (1.45 mmol) to obtain the pure
product 16a white solid. Yield: 62%; m.p: 156 C; 1H NMR
(500 MHz, CDCl3) d (ppm): 7.66 (d, J= 15.2 Hz, 1H), 7.50–
7.41 (m, 1H), 7.30–7.20 (m, 1H), 6.96 (brs, 2H), 6.72–6.62
(m, 1H), 6.34 (d, J= 15.2 Hz, 1H), 6.19–5.98 (m, 1H), 5.48–
5.20 (m, 2H), 4.63–4.45 (m, 2H), 4.18–4.01 (brs, 2H), 3.84 (s,
6H), 3.80 (s, 3H); 13C NMR (125 MHz, CDCl3) d (ppm):
164.9, 153.2, 145.7, 142.8, 138.9, 134.6, 134.3, 132.9, 124.6,
122.5, 117.7, 116.2, 114.3, 111.0, 97.4, 69.1, 60.9, 55.9; IR
(KBr) (mmax/cm
1): 3460, 3375, 3055, 2931, 2836, 1650, 1607,
1551, 1506, 1449, 1431, 1410, 1354, 1299, 1232, 1212, 1185,
1128, 1004, 983, 934, 849, 838, 819; MS (ESI, m/z): 385 [M
+H]+; HRMS (ESI, m/z) Calculated for C21H25O5N2:
385.1758, found: 385.1753 [M+H]+.
2.2.4. (E)-3-(4-Amino-3-(prop-2-ynyloxy)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (16b)
The compound 16b was prepared according to the general
method, (E)-3-(4-nitro-3-(prop-2-ynyloxy)phenyl)-N-(3,4,5-tri
methoxyphenyl)acrylamide. (600 mg, 1.46 mmol) to obtain
the pure product 16b brown solid Yield: 64%; m.p: 148 C;
1H NMR (500 MHz, CDCl3) d (ppm): 7.67 (d, J= 15.2 Hz,
1H), 7.37 (brs, 1H), 7.08 (s, 1H), 7.04 (d, J= 8.0 Hz, 1H),
6.95 (brs, 2H), 6.69 (d, J= 8.0 Hz, 1H), 6.33 (d,
J= 15.2 Hz, 1H), 4.74 (d, J= 2.2 Hz, 2H), 4.14–4.04 (m,
1H), 3.85 (s, 6H), 3.82 (s, 3H); 13C NMR (125 MHz, CDCl3)
d ppm: 164.8, 153.1, 144.7, 142.6, 139.1, 134.2, 124.6, 123.3,
116.4, 114.6, 111.5, 97.3, 78.2, 75.9, 60.9, 56.2, 55.9; IR
(KBr) (mmax/cm
1): 3445, 3322, 3277, 2934, 2838, 2122, 1675,
1609, 1546, 1505, 1448, 1409, 1353, 1330, 1296, 1263, 1227,
1210, 1189, 1161, 1130, 1034, 1016, 995, 980, 922; MS (ESI,
m/z): 383 [M+H]+; HRMS (ESI, m/z) Calculated for
C21H23O5N2: 383.1601, found: 383.1597 [M+H]
+.
2.3. General procedure for the synthesis of 1-aryl-2-propyn-1-ol
(12)
A solution of aldehyde 11a-e (5 mmol) in dry tetrahydrofuran
was added to a stirred solution of ethynylmagnesium bromide
in THF (0.5 M solution, 7.5 mmol) at 0 C. The solution was
stirred at 0 C for 2 h and then warmed to room temperature
and stirred for another 6–7 h. Saturated aqueous ammonium
chloride solution 5 mL was added, and the mixture was evap-
orated in vacuo and partitioned between ethyl acetate and sat-
urated ammonium chloride solution. The organic layer was
washed with brine, dried over anhydrous Na2SO4, and evapo-
rated in vacuo to get pure compounds that were used for next
step without further purification.
2.4. General procedure of 1-arylprop-2-yn-1-one (13)
To the stirred solution of 1-arylprop-2-yn-1-ol (1 mmol) in
dimethyl sulfoxide (DMSO), a solution of 2-iodoxy-benzoicconjugates as tubulin polymerization inhibitors and apoptotic inducers. Arabian
4 N. Sankara Rao et al.acid (IBX) (1.1 mmol) in dimethyl sulfoxide (DMSO) (10 mL)
was added at 10–15 C. Then, the reaction mixture slowly
raised the temperature to RT and allowed to stir for 4–6 h.
The reaction was monitored by TLC using ethyl acetate/hex-
ane (3:7) as a solvent system. Appropriate amount of water
was added, the reaction mixture was filtered through Celite,
and the aqueous layer was extracted with ethyl acetate. The
organic layer was washed with water and brine, dried over
anhydrous Na2SO4, and evaporated by using vacuum to get
crude compounds. The compound was purified by column
chromatography and the compound was eluted in ethyl acet-
ate/hexane (3:7) as solvent system.
2.4.1. 1-(3,4,5-Trimethoxyphenyl)prop-2-yn-1-one (13a)
Compound 13a was prepared according to the method
described for compound 13, employing 1-(3,4,5-
trimethoxyphenyl) prop-2-yn-1-ol (12a, 750 mg, 3.38 mmol)
and IBX (1.04 g, 3.72 mmol) to obtain the pure product 13a
as a light brown colour solid. (654 mg, 88% yield) m.p: 123–
126 C; 1H NMR (CDCl3, 300 MHz) d (ppm): 7.43 (s, 2H),
3.95 (s, 3H), 3.93 (s, 6H), 3.43 (s, 1H); MS (ESI) m/z 221 [M
+H]+.
2.4.2. 1-(2-Bromo-3,4,5-trimethoxyphenyl) prop-2-yn-1-one
(13b)
Compound 13b was prepared according to the method
described for compound 13, employing 1-(2-bromo-3,4,5-trime
thoxyphenyl)prop-2-yn-1-ol (12b, 750 mg, 2.50 mmol) and
IBX (770 mg, 2.75 mmol) to obtain the pure product 13b as
a brown colour solid. (638 mg, 86% yield); m.p: 80–81 C;
1H NMR (CDCl3, 300 MHz) d (ppm): 7.46 (s, 1H), 3.98 (s,
3H), 3.93 (s, 3H), 3.89 (s, 3H), 3.50 (s, 1H); MS (ESI) m/z
298 [M+H]+.
2.4.3. 1-(3,4-Dimethoxy-5-nitrophenyl) prop-2-yn-1-one (13c)
Compound 13c was prepared according to the method
described for compound 13, employing 1-(3,4-dimethoxy-5-ni
trophenyl)prop-2-yn-1-ol (12c, 750 mg, 3.16 mmol) and IBX
(973 mg, 3.48 mmol) to obtain the pure product 13c as a
brown colour solid. (617 mg, 83% yield); m.p: 103–104 C;
1H NMR (CDCl3, 300 MHz) d (ppm): 8.18 (s, 1H), 7.81 (s,
1H), 4.08 (s, 3H), 4.00 (s, 3H), 3.54 (s, 1H); MS (ESI) m/z
236 [M+H]+.
2.4.4. 1-(3-((tert-butyldimethylsilyl) oxy)-4-methoxyphenyl)
prop-2-yn-1-one (13d)
Compound 13d was prepared according to the method
described for compound 13, employing 1-(3-((tert-
butyldimethylsilyl) oxy)-4-methoxyphenyl) prop-2-yn-1-ol
(12d, 750 mg, 2.57 mmol) and IBX (791 mg, 2.83 mmol) to
obtain the pure product 13d as a brown colour solid.
(573 mg, 77% yield); m.p: 79–80 C; 1H NMR (CDCl3,
300 MHz) d (ppm): 1H NMR (500 MHz, CDCl3) d 7.83 (dd,
J= 8.5, 2.1 Hz, 1H), 7.62 (d, J= 2.1 Hz, 1H), 6.91 (d,
J= 8.5 Hz, 1H), 3.90 (s, 3H), 3.36 (s, 1H), 1.01 (s, 9H), 0.21
(s, 6H); MS (EI) m/z 291 [M+H]+.
2.4.5. 1-(4-Methoxy-3-nitrophenyl)prop-2-yn-1-one (13e)
Compound 13e was prepared according to the method
described for compound 13, employing 1-(4-methoxy-3-nitroPlease cite this article in press as: Sankara Rao, N. et al., Arylcinnamido-propionone
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(1.11 g, 3.98 mmol) to obtain the pure product 13d as a brown
colour solid. (542 mg, 73% yield); m.p: 93–94 C; 1H NMR
(CDCl3, 500 MHz) d (ppm): 8.64 (d, J= 2.2 Hz, 1H), 8.34
(dd, J= 2.2 Hz, 9.06 Hz, 1H), 7.21 (d, J= 9.06 Hz, 1H),
4.08 (s, 3H), 3.53 (s, 1H); MS (EI) m/z 206 [M+H]+.
2.5. General procedure for the synthesis of target compounds 4–6
(a-h) and 7a-f
To the stirred solution of Aryl propynones 13(a-e) (5 mmol) in
absolute ethanol substituted amino phenylcinnamides (10a-b
and 16a-b) (5 mmol) were added. The reaction was stirred for
3 h at room temperature. After the completion of reaction
(checked by TLC), the reaction mixture was diluted with water
and the crude product was filtered. The crude product was
recrystallized from methanol to get pure yellow coloured com-
pounds 4–6(a-h) and 7a-f with good yields.
2.5.1. (E)-3-(4-Methoxy-3-((Z)-3-oxo-3-(3,4,5-
trimethoxyphenyl)prop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (4a)
Yield (210 mg, 87%); yellow solid, m.p: 212 C; 1H NMR
(300 MHz, DMSO) d ppm: 12.14 (d, J= 12.4 Hz, 1H), 9.63
(s, 1H), 7.73–7.64 (dd, J= 8.0, 12.4 1H), 7.63–7.56 (m, 1H),
7.40 (s, 1H), 7.23 (s, 3H), 7.10 (s, 2H), 6.96 (d, J= 8.5 Hz,
1H), 6.67 (d, J= 15.6 Hz, 1H), 6.07 (d, J= 8.0 Hz, 1H),
4.00 (s, 3H), 3.91 (d, J= 4.0 Hz, 6H), 3.86 (s, 3H), 3.84 (s,
6H), 3.75 (d, J= 4.8 Hz, 3H). 13C NMR (75 MHz, CDCl3 + -
DMSO) d ppm: 188.79, 163.76, 152.32, 148.77, 142.86, 140.57,
139.51, 134.92, 133.97, 133.43, 129.38, 127.79, 122.80, 120.19,
111.83, 110.82, 104.26, 96.92, 93.70, 60.02, 55.59, 55.33; IR
(KBr) (vmax/cm
1): 3369, 2895, 2841, 1619, 1548, 1524, 1489,
1410; MS (ESI): m/z 579 [M+H]+; HRMS calcd for
C31H35O9N2 [M+H]
+ 579.23371, found 579.23318.
2.5.2. (E)-3-(3-((Z)-3-(2-Bromo-3,4,5-trimethoxyphenyl)-3-
oxoprop-1-enylamino)-4-methoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (4b)
Yield (233 mg, 85%); yellow solid, m.p: 134 C; 1H NMR
(300 MHz, CDCl3 + DMSO) d ppm: 11.96 (d, J= 12.8 Hz,
1H), 9.60 (bs, 1H), 7.69–7.54 (m, 2H), 7.44 (s, 1H), 7.28–7.24
(m, 1H), 7.11 (s, 2H), 6.98 (d, J= 8.5 Hz, 1H), 6.89 (s, 1H),
6.71 (d, J= 15.4 Hz, 1H), 5.77 (d, J= 7.7 Hz, 1H), 4.01 (s,
3H), 3.92 (s, 3H), 3.90 (s, 3H), 3.89 (s, 3H), 3.86 (s, 6H),
3.79 (s, 3H); 13C NMR (75 MHz, CDCl3) d ppm: 193.03,
164.27, 153.12, 152.82, 150.95, 149.56, 144.21, 143.57, 140.19,
138.06, 134.94, 134.24, 129.06, 127.79, 125.29, 120.29, 110.75,
110.70, 107.62, 106.06, 98.50, 97.17, 61.10, 61.05, 60.90,
56.14, 55.87, 55.83; IR (KBr) (vmax/cm
1): 3443, 2936, 2841,
1625, 1552, 1506, 1469, 1426; MS (ESI): m/z 657 [M+H]+;
HRMS calcd for C31H34O9N2 Br [M+H]
+ 657.14422, found
657.14464.
2.5.3. (E)-3-(3-((Z)-3-(3,4-Dimethoxy-5-nitrophenyl)-3-
oxoprop-1-enylamino)-4-methoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (4c)
Yield (216 mg, 85%); yellow solid, m.p: 165 C; 1H NMR
(300 MHz, DMSO) d ppm: 12.23 (d, J= 12.5 Hz, 1H), 9.79
(bs, 1H), 7.90 (s, 1H), 7.82 (s, 1H), 7.70–7.66 (m, 1H), 7.62conjugates as tubulin polymerization inhibitors and apoptotic inducers. Arabian
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7.13 (s, 2H), 7.03 (d, J= 8.3 Hz, 1H), 6.73 (d, J= 15.5 Hz,
1H), 6.12 (d, J= 7.5 Hz, 1H), 4.04 (s, 9H), 3.87 (s, 6H), 3.78
(s, 3H); IR (KBr) (vmax/cm
1): 3440, 2941, 2840, 1682, 1648,
1608, 1535, 1508; MS (ESI): m/z 594 [M+H]+; HRMS calcd
for C30H32O10N3 [M+H]
+ 594.20822, found 594.20827.
2.5.4. (E)-3-(3-((Z)-3-(3-Amino-4,5-dimethoxyphenyl)-3-
oxoprop-1-enylamino)-4-methoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (4d)
Yield (179 mg, 76%); yellow solid, m.p: 127 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.13 (d, J= 12.4 Hz, 1H), 8.62
(bs, 1H), 7.62 (d, J= 15.4 Hz, 1H), 7.50–7.39 (dd, J= 7.9,
12.4, 1H), 7.22 (s, 1H), 7.10 (s, 2H), 7.03 (d, J= 9.8 Hz,
3H), 6.77 (d, J= 8.4 Hz, 1H), 6.57 (d, J= 15.4 Hz, 1H),
5.99 (d, J= 7.9 Hz, 1H), 3.87 (s, 6H), 3.83 (s, 6H), 3.82 (s,
6H); 13C NMR (75 MHz, CDCl3 + DMSO) d ppm: 189.65,
163.80, 155.63, 152.38, 151.98, 148.67, 142.18, 140.15, 139.44,
137.94, 134.79, 134.39, 129.67, 127.74, 122.78, 119.89, 111.44,
110.75, 107.63, 100.49, 96.94, 93.95, 60.08, 59.10, 55.51,
55.34, 55.13; IR (KBr) (vmax/cm
1): 3638, 3343, 3280, 1646,
1585, 1537, 1498; MS (ESI): m/z 564 [M+H]+; HRMS calcd
for C30H34O8N3 [M+H]
+ 564.23404, found 564.23319.
2.5.5. (E)-3-(3-(((Z)-3-(3-((tert-butyldimethylsilyl)oxy)-4-
methoxyphenyl)-3-oxoprop-1-en-1-yl)amino)-4-
methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide (4e)
Yield (238 mg, 88%); yellow solid, m.p: 151 C; 1H NMR
(300 MHz, CDCl3) d 12.16 (d, J= 12.4 Hz, 1H), 8.88 (bs,
1H), 7.67–7.59 (m, 1H), 7.57–7.53 (m, 2H), 7.46 (dd,
J= 12.4, 4.5 Hz, 1H), 7.20–7.15 (m, 3H), 6.99 (d,
J= 8.4 Hz, 1H), 6.90 (d, J= 8.6 Hz, 1H), 6.74 (d,
J= 8.4 Hz, 1H), 6.56 (d, J= 15.4 Hz, 1H), 6.09 (d,
J= 7.9 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 6H), 3.84 (s, 6H), 0.99
(s, 9H), 0.15 (s, 6H); MS (ESI): m/z 649 [M+H]+.
2.5.6. (E)-3-(3-((Z)-3-(3-Hydroxy-4-methoxyphenyl)-3-
oxoprop-1-enylamino)-4-methoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (4f)
Yield (176 mg, 79%); yellow solid, m.p: 114 C; 1H NMR
(300 MHz, CDCl3 + DMSO) d ppm: 12.07 (d, J= 12.4 Hz,
1H), 9.54 (bs, 1H), 8.19 (bs, 1H), 7.62 (d, J= 15.6 Hz, 1H),
7.58–7.47 (m, 3H), 7.36 (s, 1H), 7.21–7.16 (m, 1H), 7.13 (s,
2H), 6.95–6.88 (m, 2H), 6.69 (d, J= 15.6 Hz, 1H), 6.05 (d,
J= 7.9 Hz, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.87 (s, 6H), 3.80
(s, 3H); IR (KBr) (vmax/cm
1): 3314, 2933, 2840, 1665, 1608,
1547, 1508, 1479; MS (ESI): m/z 535 [M+H]+; HRMS calcd
for C29H31O8N2 [M+H]
+ 535.20749, found 535.20646.
2.5.7. (E)-3-(4-Methoxy-3-((Z)-3-(4-methoxy-3-
nitrophenyl)-3-oxoprop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (4g)
Yield (202 mg, 86%); yellow solid, m.p: 133 C; 1H NMR
(300 MHz, DMSO) d ppm: 12.26 (d, J= 12.4 Hz, 1H), 9.78
(bs, 1H), 8.51 (s, 1H), 8.27 (d, J= 8.5 Hz, 1H), 7.80–7.70
(m, 1H), 7.65–7.58 (m, 2H), 7.48 (s, 1H), 7.29–7.21 (m, 2H),
7.12 (s, 1H), 6.99 (d, J= 8.3 Hz, 1H), 6.71 (d, J= 15.7 Hz,
1H), 6.09 (d, J= 7.3 Hz, 1H), 4.0 (s, 6H), 3.86 (s, 6H), 3.78
(s, 3H); IR (KBr) (vmax/cm
1): 3441, 2938, 2841, 1611, 1586,
1506, 1474, 1411; MS (ESI): m/z 564 [M+H]+.Please cite this article in press as: Sankara Rao, N. et al., Arylcinnamido-propionone
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oxoprop-1-enylamino)-4-methoxyphenyl)-N-(3,5-
dimethoxyphenyl)acrylamide (4h)
Yield (174 mg, 78%); yellow solid, m.p: 144 C; 1H NMR
(300 MHz, DMSO) d ppm: 12.09 (d, J= 12.4 Hz, 1H), 9.67
(bs, 1H), 7.67–7.54 (m, 3H), 7.43–7.32 (m, 2H), 7.22 (d,
J= 8.3 Hz, 1H), 7.13 (s, 2H), 6.97 (d, J= 8.4 Hz, 1H), 6.83
(d, J= 8.2 Hz, 1H), 6.71 (d, J= 15.5 Hz, 1H), 6.07 (d,
J= 7.9 Hz, 1H), 4.18 (bs, 2H), 4.02 (s, 3H), 3.92 (s, 3H),
3.87 (s, 6H), 3.80 (d, J= 2.6 Hz, 3H); 13C NMR (75 MHz,
CDCl3 + DMSO) d ppm: 189.54, 163.77, 152.36, 149.40,
148.69, 141.79, 139.54, 136.20, 134.96, 133.39, 131.58, 129.72,
127.76, 122.60, 120.11, 117.37, 112.60, 111.29, 110.72, 108.85,
96.90, 93.96, 60.01, 55.53, 55.33, 54.94; IR (KBr)
(vmax/cm
1): 3648, 3312, 3247, 2840, 1624, 1546, 1507, 1477;
MS (ESI): m/z 534 [M+H]+; HRMS calcd for C29H32O7N3
[M+H]+ 534.22348, found 534.22216.
2.5.9. (E)-3-(3,4-Dimethoxy-5-((Z)-3-oxo-3-(3,4,5-
trimethoxyphenyl)prop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (5a)
Yield (190 mg, 81%); yellow solid, m.p: 208 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.20 (d, J= 12.8 Hz, 1H), 7.90
(s, 1H), 7.65 (d, J= 15.4 Hz, 1H), 7.54–7.42 (dd, J= 7.5,
12.8 Hz, 1H), 7.23 (s, 2H), 7.01 (s, 2H), 6.93 (s, 1H), 6.76 (s,
1H), 6.53 (d, J= 15.4 Hz, 1H), 6.04 (d, J= 7.5 Hz, 1H),
4.00 (s, 3H), 3.93 (s, 6H), 3.92 (s, 3H), 3.88 (s, 3H), 3.85 (s,
6H), 3.84 (s, 3H); 13C NMR (75 MHz, CDCl3 + DMSO) d
ppm: 189.18, 163.53, 152.56, 152.44, 152.31, 142.60, 140.65,
139.73, 138.23, 134.60, 134.02, 133.76, 130.88, 121.45, 105.41,
104.28, 97.02, 93.84, 60.12, 55.59, 55.36; IR (KBr)
(vmax/cm
1): 3389, 2980, 2841, 1626, 1565, 1508, 1467, 1426;
MS (ESI): m/z 609 [M+H]+; HRMS calcd for C32H37O10N2
[M+H]+ 609.24427, found 609.24371.
2.5.10. (E)-3-(3-((Z)-3-(2-Bromo-3,4,5-trimethoxyphenyl)-3-
oxoprop-1-enylamino)-4,5-dimethoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (5b)
Yield (228 mg, 86%); yellow solid, m.p: 151 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.04 (d, J= 12.8 Hz, 1H), 7.96
(s, 1H), 7.64 (d, J= 15.3 Hz, 1H), 7.54–7.42 (dd, J= 7.5,
12.8 Hz, 1H), 6.99 (s, 2H), 6.96 (s, 1H), 6.89 (s, 1H), 6.76 (s,
1H), 6.56 (d, J= 15.4 Hz, 1H), 5.78 (d, J= 7.5 Hz, 1H),
3.99 (s, 3H), 3.91 (s, 3H), 3.90 (s, 3H), 3.89 (s, 3H), 3.87 (s,
3H), 3.83 (s, 6H), 3.82 (s, 3H); 13C NMR (125 MHz, CDCl3)
d ppm: 192.92, 163.99, 153.24, 153.04, 152.83, 150.92, 144.29,
143.48, 141.12, 139.15, 138.07, 134.58, 133.85, 130.98, 121.36,
107.95, 107.35, 106.14, 105.17, 98.80, 97.50, 61.12, 61.05,
60.93, 60.90, 56.16, 55.99, 55.92; IR (KBr) (vmax/cm
1):
3445, 2985, 2840, 1646, 1589, 1535, 1489, 1468; MS (ESI):
m/z 689 [M+H]+; HRMS calcd for C32H38O10N2 Br [M
+H]+ 689.17043, found 689.15289.
2.5.11. (E)-3-(3-((Z)-3-(3,4-Dimethoxy-5-nitrophenyl)-3-
oxoprop-1-enylamino)-4,5-dimethoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (5c)
Yield (204 mg, 85%); yellow solid, m.p: 172 C; 1H NMR
(300 MHz, DMSO) d ppm: 12.29 (d, J= 12.8 Hz, 1H), 9.74
(s, 1H), 7.91–7.88 (m, 1H), 7.82–7.79 (m, 1H), 7.78–7.68 (dd,
J= 7.7, 12.8 1H), 7.66–7.55 (m, 2H), 7.11 (s, 2H), 6.89 (s,
1H), 6.75 (d, J= 15.6 Hz, 1H), 6.09 (d, J= 7.7 Hz, 1H),conjugates as tubulin polymerization inhibitors and apoptotic inducers. Arabian
6 N. Sankara Rao et al.4.04 (s, 3H), 4.03 (s, 3H), 4.02 (s, 3H), 3.96 (s, 3H), 3.88 (s, 6H),
3.80 (s, 3H); 13C NMR (75 MHz, CDCl3 + DMSO) d ppm:
186.37, 163.50, 153.31, 152.52, 152.44, 144.41, 143.84, 143.66,
139.58, 138.27, 134.64, 134.02, 133.67, 133.34, 130.93, 121.61,
114.40, 113.92, 106.00, 105.35, 97.05, 93.01, 61.32, 60.18,
60.11, 55.97, 55.36; IR (KBr) (vmax/cm
1): 3378, 2941, 2838,
1632, 1608, 1586, 1537; MS (ESI): m/z 624 [M+H]+; HRMS
calcd for C31H34O11N3 [M+H]
+ 624.21879, found 624.21885.
2.5.12. (E)-3-(3-((Z)-3-(3-Amino-4,5-dimethoxyphenyl)-3-
oxoprop-1-enylamino)-4,5-dimethoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (5d)
Yield (192 mg, 84%); yellow solid, m.p: 140 C; 1H NMR
(300 MHz, DMSO) d ppm: 12.18 (d, J= 12.1 Hz, 1H), 9.64 (s,
1H), 7.61 (d, J= 15.6 Hz, 1H), 7.58–7.54 (m, 2H), 7.11 (s, 2H),
7.04 (d, J= 7.3 Hz, 1H), 6.96 (s, 1H), 6.84 (s, 1H), 6.73 (d,
J= 15.6 Hz, 1H), 6.03 (d, J= 7.5 Hz, 1H), 4.26 (bs, 2H), 4.00
(s, 3H), 3.94 (s, 3H), 3.92 (s, 3H), 3.87 (s, 6H), 3.86 (s, 3H), 3.80
(s, 3H); 13C NMR (75 MHz, CDCl3 + DMSO) d ppm: 189.85,
163.95, 163.57, 152.45, 152.41, 152.24, 152.00, 140.70, 140.48,
139.93, 139.80, 134.73, 134.60, 133.90, 130.26, 120.08, 107.78,
107.70, 101.02, 100.70, 97.06, 96.98, 60.13, 59.15, 55.34, 55.16,
55.04; IR (KBr) (vmax/cm
1): 3450, 2933, 2849, 2360, 1625,
1548, 1506; MS (ESI): m/z 594 [M+H]+; HRMS calcd for
C31H36O9N3 [M+H]
+ 594.24461, found 594.24422.
2.5.13. (E)-3-(3-((Z)-3-(3-Hydroxy-4-methoxyphenyl)-3-
oxoprop-1-enylamino)-4,5-dimethoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (5f)
Yield (185 mg, 85%); yellow solid, m.p: 211 C; 1H NMR
(300 MHz, CDCl3): d 12.14 (d, J= 12.08 Hz, 1H), 8.31 (s,
1H), 7.64 (d, J= 15.8 Hz, 1H), 7.56–7.52 (m, 2H), 7.44–7.35
(dd, J= 8.3, 12.0 Hz, 1H), 7.04 (s, 2H), 6.90 (s, 2H), 6.70 (s,
1H), 6.59 (d, J= 15.8 Hz, 1H), 6.00 (d, J= 8.3 Hz, 1H),
3.97 (s, 3H), 3.95 (s, 3H), 3.85 (s, 12H); 13C NMR (75 MHz,
CDCl3 + DMSO) d ppm: 189.39, 163.57, 152.54, 152.42,
150.17, 145.56, 141.88, 139.75, 134.67, 134.00, 133.60, 131.81,
130.86, 121.46, 119.35, 113.81, 109.97, 105.34, 105.02, 96.96,
93.98, 60.13, 60.08, 55.36, 55.32, 55.26; IR (KBr) (vmax/
cm1): 3333, 2923, 2851, 2359, 1671, 1629, 1608, 1548; MS
(ESI): m/z 565 [M+H]+; HRMS calcd for C30H33O9N2 [M
+H]+ 565.21806, found 565.21720.
2.5.14. (E)-3-(3,4-Dimethoxy-5-((Z)-3-(4-methoxy-3-
nitrophenyl)-3-oxoprop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (5g)
Yield (190 mg, 83%); yellow solid, m.p: 243 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.26 (d, J= 12.6 Hz, 1H), 9.52
(s, 1H), 8.02 (d, J= 15.6 Hz, 1H), 7.89–7.79 (m, 2H), 7.40
(s, 1H), 7.11 (s, 2H), 6.99 (s, 1H), 6.93 (d, J= 7.9 Hz, 1H),
6.77 (d, J= 15.6 Hz, 1H), 6.71–6.61 (m, 1H), 6.00 (d,
J= 8.5 Hz, 1H), 4.06 (s, 3H), 4.03 (s, 3H), 3.99 (s, 3H), 3.96
(s, 3H), 3.84 (s, 6H); IR (KBr) (vmax/cm
1): 3355, 3012,
1681, 1636, 1612, 1588, 1537; MS (ESI): m/z 594 [M+H]+.
2.5.15. (E)-3-(3-((Z)-3-(3-Amino-4-methoxyphenyl)-3-
oxoprop-1-enylamino)-4,5-dimethoxyphenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (5h)
Yield (174 mg, 80%); yellow solid, m.p: 182 C; 1H NMR
(300 MHz, DMSO) d ppm: 12.16 (d, J= 12.4 Hz, 1H), 9.47Please cite this article in press as: Sankara Rao, N. et al., Arylcinnamido-propionone
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(s, 1H), 7.10 (s, 2H), 7.02 (s, 1H), 6.82 (d, J= 7.5 Hz, 1H),
6.71 (d, J= 15.7 Hz, 1H), 6.64–6.50 (m, 1H), 6.05 (d,
J= 7.7 Hz, 1H), 4.00 (s, 3H), 3.92 (s, 3H), 3.87 (s, 6H), 3.82
(s, 6H); IR (KBr) (vmax/cm
1): 3409, 2980, 2845, 2578, 1657,
1609, 1545, 1510; MS (ESI): m/z 564 [M+H]+; HRMS calcd
for C30H34O8N3 [M+H]
+ 564.23404, found 564.23314.
2.5.16. (E)-3-(3-(Allyloxy)-4-((Z)-3-oxo-3-(3,4,5-
trimethoxyphenyl)prop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (6a)
Yield (195 mg, 83%); yellow solid, m.p: 141 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.23 (d, J= 12.4 Hz, 1H), 7.77
(bs, 1H), 7.66 (d, J= 15.4 Hz, 1H), 7.57–7.46 (dd, J= 7.5,
12.4 Hz, 1H), 7.21 (s, 2H), 7.16–7.07 (m, 2H), 7.05–6.96 (m,
3H), 6.47 (d, J= 15.4 Hz, 1H), 6.21–6.10 (m, 1H), 6.06 (d,
J= 7.5 Hz, 1H), 5.59 (d, J= 17.5 Hz, 1H), 5.36 (d,
J= 10.6 Hz, 1H), 4.69 (d, J= 4.7 Hz, 2H), 3.92 (s, 6H),
3.91 (s, 3H), 3.84 (s, 6H), 3.83 (s, 3H); 13C NMR (75 MHz,
CDCl3) d ppm: 190.08, 164.31, 153.27, 152.99, 147.17,
142.30, 141.41, 134.61, 132.27, 131.60, 129.80, 121.79, 119.59,
118.06, 112.96, 111.53, 104.89, 97.61, 95.13, 69.47, 60.91,
56.18, 55.98; IR (KBr) (vmax/cm
1): 3321, 2927, 2840, 1645,
1608, 1525, 1489; MS (ESI): m/z 605 [M+H]+; HRMS calcd
for C33H37O9N2 [M+H]
+ 605.24936, found 605.24869.
2.5.17. (E)-3-(3-(Allyloxy)-4-((Z)-3-(2-bromo-3,4,5-
trimethoxyphenyl)-3-oxoprop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (6b)
Yield (218 mg, 82%); yellow solid, m.p: 113 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.08 (d, J= 12.0 Hz, 1H), 7.67
(d, J= 15.1 Hz, 1H), 7.60 (bs, 1H), 7.55–7.46 (dd, J= 8.3,
12.0 Hz, 1H), 7.15 (s, 2H), 7.04 (s, 1H), 6.97 (s, 2H), 6.87 (s,
1H), 6.47 (d, J= 15.4 Hz, 1H), 6.22–6.05 (m, 1H), 5.80 (d,
J= 8.3 Hz, 1H), 5.64 (d, J= 17.2 Hz, 1H), 5.37 (d,
J= 10.6 Hz, 1H), 4.69 (d, J= 3.7 Hz, 2H), 3.91 (s, 3H), 3.90
(s, 3H), 3.86 (s, 3H), 3.85 (s, 6H), 3.83 (s, 3H); 13C NMR
(75 MHz, CDCl3) d ppm: 192.82, 164.24, 153.17, 152.76,
150.87, 147.12, 144.17, 142.20, 141.27, 138.13, 134.64, 134.33,
132.01, 131.10, 130.11, 121.60, 119.83, 118.06, 113.01, 111.35,
107.87, 106.10, 99.40, 97.32, 69.29, 61.10, 61.01, 60.93, 56.09,
55.91; IR (KBr) (vmax/cm
1): 3343, 2928, 2851, 1656, 1634,
1543, 1528; MS (ESI): m/z 683 [M+H]+; HRMS calcd for
C33 H36 O9 N2 Br [M+H]
+ 683.15987, found 683.15987.
2.5.18. (E)-3-(3-(Allyloxy)-4-((Z)-3-(3,4-dimethoxy-5-
nitrophenyl)-3-oxoprop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (6c)
Yield (207 mg, 86%); yellow solid, m.p: 134 C; 1H NMR
(300 MHz, CDCl3) d 12.28 (d, J= 12.8 Hz, 1H), 7.88 (d,
J= 1.8 Hz, 1H), 7.78 (d, J= 1.8 Hz, 1H), 7.68 (d,
J= 15.4 Hz, 1H), 7.63–7.54 (dd, J= 7.5, 12.8 Hz, 1H), 7.40
(s, 1H), 7.22–7.15 (m, 2H), 7.08 (s, 1H), 6.96 (s, 2H), 6.44 (d,
J= 15.4 Hz, 1H), 6.26–6.09 (m, 1H), 6.04 (d, J= 7.5 Hz,
1H), 5.64 (d, J= 17.3 Hz, 1H), 5.41 (d, J= 10.6 Hz, 1H),
4.75 (d, J= 4.8 Hz, 2H), 4.04 (s, 3H), 4.00 (s, 3H), 3.87 (s,
6H), 3.84 (s, 3H); 13C NMR (75 MHz, CDCl3) d ppm:
187.09, 164.23, 153.96, 153.17, 147.10, 145.26, 144.06, 143.27,
141.35, 134.56, 134.41, 134.34, 132.12, 131.01, 130.11, 121.56,
119.68, 117.97, 115.18, 114.34, 113.13, 111.58, 97.38, 94.17,
69.33, 62.01, 60.91, 56.42, 55.90; IR (KBr) (vmax/cm
1):conjugates as tubulin polymerization inhibitors and apoptotic inducers. Arabian
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[M+H]+; HRMS calcd for C32H34O10N3 [M+H]
+
620.22387, found 620.22314.
2.5.19. (E)-3-(3-(Allyloxy)-4-((Z)-3-(3-amino-4,5-
dimethoxyphenyl)-3-oxoprop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (6d)
Yield (195 mg, 85%); yellow solid, m.p: 212 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.27 (d, J= 12.8 Hz, 1H), 7.86
(d, J= 1.5 Hz, 1H), 7.77 (d, J= 1.51 Hz, 1H), 7.67 (d,
J= 15.4 Hz, 1H), 7.62–7.52 (dd, J= 7.5, 12.8 Hz, 2H),
7.22–7.11 (m, 2H), 7.05 (s, 1H), 6.98 (s, 2H), 6.46 (d,
J= 15.4 Hz, 1H), 6.22–6.07 (m, 1H), 6.03 (d, J= 7.5 Hz,
1H), 5.63 (d, J= 17.0 Hz, 1H), 5.40 (d, J= 10.5 Hz, 1H),
4.72 (d, J= 4.8 Hz, 2H), 4.03 (s, 3H), 3.99 (s, 3H), 3.85 (s,
6H), 3.84 (s, 3H); 13C NMR (75 MHz, CDCl3) d ppm:
187.14, 164.16, 154.00, 153.22, 147.15, 145.31, 144.11, 143.27,
141.44, 134.45, 132.15, 131.08, 130.11, 121.63, 119.63, 118.01,
115.23, 114.36, 113.16, 111.60, 97.39, 94.21, 69.38, 62.04,
60.93, 56.45, 55.94; IR (KBr) (vmax/cm
1): 3317, 2923, 2850,
1678, 1625, 1538, 1507; MS (ESI): m/z 590 [M+H]+; HRMS
calcd for C32H36O8N3 [M+H]
+ 590.24969, found 590.24933.
2.5.20. (E)-3-(3-(allyloxy)-4-(((Z)-3-(3-((tert-
butyldimethylsilyl)oxy)-4-methoxyphenyl)-3-oxoprop-1-en-1-
yl)amino)phenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide (6e)
Yield (226 mg, 86%); yellow solid, m.p: 183 C; 1H NMR
(500 MHz, CDCl3) d ppm: 12.22 (d, J= 12.4 Hz, 1H), 7.66
(d, J= 15.2 Hz, 1H), 7.59–7.55 (m, 2H), 7.51–7.44 (m, 2H),
7.12 (s, 2H), 7.03 (s, 1H), 6.98 (s, 1H), 6.87 (d, J= 8.5 Hz,
1H), 6.43 (d, J= 15.2 Hz, 1H), 6.16–6.08 (m, 1H), 6.05 (d,
J= 8.0 Hz, 1H), 5.63 (d, J= 17.9 Hz, 1H), 5.37 (d,
J= 10.6 Hz, 1H), 4.70 (d, J= 4.7 Hz, 2H), 3.86 (s, 9H), 3.83
(s, 3H), 1.60 (s, 9H), 1.01 (s, 6H); MS (ESI): m/z 675 [M+H]+.
2.5.21. (E)-3-(3-(Allyloxy)-4-((Z)-3-(3-hydroxy-4-
methoxyphenyl)-3-oxoprop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (6f)
Yield (172 mg, 79%); yellow solid, m.p: 196 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.22 (d, J= 12.0 Hz, 1H), 7.65
(d, J= 15.8 Hz, 1H), 7.58–7.50 (m, 2H), 7.50–7.41 (dd,
J= 7.5, 12.0 Hz, 1H), 7.09 (s, 2H), 6.99 (d, J= 6.9 Hz, 3H),
6.87 (d, J= 8.3 Hz, 1H), 6.43 (d, J= 15.3 Hz, 1H), 6.19–
6.08 (m, 1H), 6.04 (d, J= 7.5 Hz, 1H), 5.73 (bs, 1H), 5.62
(d, J= 17.3 Hz, 1H), 5.36 (d, J= 10.7 Hz, 1H), 4.66 (d,
J= 2.0 Hz, 2H), 3.94 (s, 3H), 3.85 (s, 6H), 3.83 (s, 3H); 13C
NMR (75 MHz, CDCl3) d ppm: 190.02, 153.23, 149.68,
147.03, 145.33, 141.80, 141.69, 134.48, 132.66, 132.24, 131.77,
130.88, 129.39, 128.76, 121.88, 120.56, 119.21, 117.90, 113.70,
112.67, 111.40, 109.95, 97.40, 95.19, 69.32, 68.13, 60.97,
56.00; IR (KBr) (vmax/cm
1): 3394, 2924, 2852, 2359, 1624,
1594, 1548, 1506; MS (ESI): m/z 561 [M+H]+.
2.5.22. (E)-3-(3-(Allyloxy)-4-((Z)-3-(4-methoxy-3-
nitrophenyl)-3-oxoprop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (6g)
Yield (190 mg, 83%); yellow solid, m.p: 201 C; 1H NMR
(300 MHz, DMSO) d ppm: 12.31 (d, J= 12.5 Hz, 1H), 9.49
(s, 1H), 8.45 (s, 1H), 8.19 (d, J= 8.7 Hz, 1H), 7.68–7.58 (m,
2H), 7.49 (s, 1H), 7.27–7.17 (m, 3H), 7.12 (s, 2H), 7.11 (s,
1H), 6.66 (d, J= 15.6 Hz, 1H), 6.08 (d, J= 7.8 Hz, 1H),Please cite this article in press as: Sankara Rao, N. et al., Arylcinnamido-propionone
Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.07.0145.71 (d, J= 17.3 Hz, 1H), 5.43 (d, J= 10.7 Hz, 1H), 4.77 (s,
2H), 4.05 (s, 3H), 3.88 (s, 6H), 3.81 (s, 3H); 13C NMR
(75 MHz, DMSO) d ppm: 186.23, 163.74, 154.34, 152.38,
146.49, 142.82, 139.56, 138.68, 134.87, 132.58, 131.80, 130.90,
130.43, 129.89, 124.13, 121.33, 120.11, 117.21, 112.79, 112.72,
110.82, 96.83, 93.48, 68.74, 60.11, 56.25, 55.34; IR (KBr) (vmax/
cm1): 3433, 2828, 1621, 1594, 1548, 1509, 1498; MS (ESI): m/
z 590 [M+H]+; HRMS calcd for C31H32O9N3 [M+H]
+
590.21331, found 590.21301.
2.5.23. (E)-3-(3-(Allyloxy)-4-((Z)-3-(3-amino-4-
methoxyphenyl)-3-oxoprop-1-enylamino)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (6h)
Yield (183 mg, 84%); yellow solid, m.p: 215 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.27 (m, 1H), 8.16–8.07 (m, 1H),
7.93–7.82 (m, 1H), 7.64 (d, J= 15.2 Hz, 1H), 7.37 (d,
J= 8.7 Hz, 1H), 7.12–6.93 (m, 6H), 6.67 (d, J= 8.0 Hz,
1H), 6.46 (dd, J= 15.3, 7.3 Hz, 1H), 6.34 (d, J= 15.3 Hz,
1H), 6.19–5.96 (m, 2H), 5.62 (d, J= 17.5 Hz, 1H), 5.45–5.27
(m, 1H), 4.72–4.54 (m, 2H), 3.99 (s, 3H), 3.84 (s, 6H), 3.82
(s, 3H); IR (KBr) (vmax/cm
1): 3373, 2924, 2852, 1592, 1545,
1506, 1474; MS (ESI): m/z 560 [M+H]+; HRMS calcd for
C31H34O7N3 [M+H]
+v 560.23913, found 560.23850.
2.5.24. (E)-3-(4-((Z)-3-Oxo-3-(3,4,5-trimethoxyphenyl)prop-
1-enylamino)-3-(prop-2-ynyloxy)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (7a)
Yield (186 mg, 79%); yellow solid, m.p: 220 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.19 (d, J= 12.5 Hz, 1H), 7.71
(d, J= 15.3 Hz, 1H), 7.65 (s, 1H), 7.52 (dd, J= 12.4,
8.1 Hz, 1H), 7.26 (s, 1H), 7.22 (s, 2H), 7.17 (s, 2H), 6.98 (s,
2H), 6.48 (d, J= 15.3 Hz, 1H), 6.08 (d, J= 8.0 Hz, 1H),
4.90 (s, 2H), 3.93 (s, 6H), 3.92 (s, 3H), 3.86 (s, 6H), 3.84 (s,
3H), 2.58 (s, 1H); IR (KBr) (vmax/cm
1): 3356, 3268, 2841,
1668, 1632, 1570, 1548; MS (ESI): m/z 603 [M+H]+; HRMS
calcd for C33H35O9N2 [M+H]
+ 603.23371, found 603.23352.
2.5.25. (E)-3-(4-((Z)-3-(2-Bromo-3,4,5-trimethoxyphenyl)-3-
oxoprop-1-enylamino)-3-(prop-2-ynyloxy)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (7b)
Yield (229 mg, 86%); yellow solid, m.p: 187 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.02 (d, J= 12.7 Hz, 1H), 7.70
(d, J= 15.2 Hz, 2H), 7.53–7.45 (m, 1H), 7.23 (s, 1H), 7.16
(s, 2H), 6.98 (s, 2H), 6.88 (s, 1H), 6.50 (d, J= 15.4 Hz, 1H),
5.82 (d, J= 7.7 Hz, 1H), 4.87 (s, 2H), 3.92 (s, 3H), 3.90 (s,
3H), 3.86 (s, 3H), 3.85 (s, 6H), 3.83 (s, 3H), 2.58 (s, 1H); 13C
NMR (75 MHz, CDCl3) d ppm: 192.84, 164.21, 153.18,
152.74, 150.89, 146.05, 144.27, 142.36, 141.17, 137.94, 134.65,
134.31, 131.27, 130.09, 122.36, 120.05, 113.35, 111.76, 107.95,
106.20, 99.52, 97.33, 77.52, 76.83, 61.11, 61.02, 60.94, 56.38,
56.10, 55.91; IR (KBr) (vmax/cm
1): 3447, 2935, 2851, 1674,
1648, 1575, 1555; MS (ESI): m/z 681 [M+H]+; HRMS calcd
for C33H34O9N2 Br [M+H]
+ 681.14422, found 681.14415.
2.5.26. (E)-3-(4-((Z)-3-(3,4-Dimethoxy-5-nitrophenyl)-3-
oxoprop-1-enylamino)-3-(prop-2-ynyloxy)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (7c)
Yield (193 mg, 80%); yellow solid, m.p: 216 C; 1H NMR
(300 MHz, CDCl3) d 12.30 (d, J= 12.6 Hz, 1H), 8.90 (s,
1H), 7.79–7.68 (m, 3H), 7.62 (s, 1H), 7.43 (s, 1H), 7.31 (d,
J= 7.4 Hz, 1H), 7.20 (s, 2H), 6.69 (d, J= 7.4 Hz, 1H), 6.58conjugates as tubulin polymerization inhibitors and apoptotic inducers. Arabian
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J= 6.4 Hz, 1H), 4.81 (d, J= 2.2 Hz, 1H), 4.06 (s, 3H), 4.05
(s, 3H), 3.99 (s, 6H), 3.86 (s, 3H), 2.59 (s, 1H); IR (KBr) (vmax/
cm1): 3366, 3277, 2925, 1674, 1636, 1598, 1573; MS (ESI): m/
z 618 [M+H]+; HRMS calcd for C32H32O10N3 [M+H]
+
618.20822, found 618.20835.
2.5.27. (E)-3-(4-((Z)-3-(3-Amino-4,5-dimethoxyphenyl)-3-
oxoprop-1-enylamino)-3-(prop-2-ynyloxy)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (7d)
Yield (174 mg, 77%); yellow solid, m.p: 118 C; 1H NMR
(300 MHz, CDCl3) d ppm: 12.19 (m, 1H), 7.73–7.63 (m, 2H),
7.41 (s, 1H), 7.23 (s, 1H), 7.14 (s, 1H), 7.07 (d, J= 6.3 Hz,
1H), 7.05–6.96 (m, 4H), 6.69 (d, J= 8.0 Hz, 1H), 6.51–6.42
(m, 1H), 6.34 (d, J= 15.3 Hz, 1H), 6.08–5.98 (m, 1H), 4.89
(d, J= 6.5 Hz, 1H), 4.74 (d, J= 2.2 Hz, 1H), 3.90 (s, 3H),
3.87 (s, 3H), 3.85 (s, 6H), 3.83 (s, 3H), 2.56 (s, 1H); 13C
NMR (75 MHz, CDCl3) d ppm: 190.65, 164.36, 153.17,
152.69, 145.85, 142.13, 141.28, 140.27, 138.79, 134.89, 134.71,
134.31, 131.64, 129.52, 122.47, 113.02, 111.77, 111.50, 108.34,
101.53, 97.41, 95.34, 77.66, 76.76, 60.93, 59.92, 56.31, 55.91,
55.71; IR (KBr) (vmax/cm
1): 3261, 2924, 2851, 1625, 1593,
1544, 1506. MS (ESI): m/z 588 [M+H]+; HRMS calcd for
C32H34O8N3 [M+H]
+ 588.23404, found 588.23373.
2.5.28. (E)-3-(4-(((Z)-3-(3-((tert-butyldimethylsilyl)oxy)-4-
methoxyphenyl)-3-oxoprop-1-en-1-yl)amino)-3-(prop-2-yn-1-
yloxy)phenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide (7e)
Yield (229 mg, 87%); yellow solid, m.p: 167 C; 1H NMR
(500 MHz, CDCl3) d ppm: 12.15 (d, J= 12.2 Hz, 1H), 7.70
(d, J= 15.4 Hz, 1H), 7.57 (dd, J= 8.3, 1.9 Hz, 1H), 7.51 (d,
J= 1.9 Hz, 1H), 7.46 (dd, J= 12.2, 8.0 Hz, 1H), 7.24 (s,
1H), 7.13 (s, 2H), 7.00 (s, 2H), 6.87 (d, J= 8.5 Hz, 1H), 6.48
(d, J= 15.4 Hz, 1H), 6.06 (d, J= 8.0 Hz, 1H), 4.87 (s, 2H),
3.86 (s, 3H), 3.85 (s, 6H), 3.84 (s, 3H), 2.55 (s, 1H), 1.01 (s,
9H), 0.18 (s, 6H); MS (ESI): m/z 673 [M+H]+.
2.5.29. (E)-3-(4-((Z)-3-(3-Hydroxy-4-methoxyphenyl)-3-
oxoprop-1-enylamino)-3-(prop-2-ynyloxy)phenyl)-N-(3,4,5-
trimethoxyphenyl)acrylamide (7f)
Yield (181 mg, 83%); yellow solid, m.p: 170 C; 1H NMR
(300 MHz, CDCl3) d ppm: 9.70 (bs, 1H), 8.57 (bs, 1H), 7.63
(d, J= 16.0 Hz, 1H), 7.58–7.54 (m, 2H), 7.51 (s, 1H), 7.32
(s, 1H), 7.24 (s, 2H), 7.12 (s, 2H), 6.91 (d, J= 8.4 Hz, 1H),
6.69 (d, J= 15.6 Hz, 1H), 6.09 (d, J= 8.0 Hz, 1H), 4.97 (s,
2H), 3.94 (s, 3H), 3.87 (s, 6H), 3.79 (s, 3H), 2.59 (s, 1H); 13C
NMR (75 MHz, CDCl3 + DMSO) d ppm: 189.34, 163.94,
152.42, 150.40, 145.66, 145.28, 141.29, 139.80, 134.93, 133.36,
131.62, 131.20, 129.07, 122.22, 119.82, 119.50, 113.86, 112.56,
111.08, 110.03, 96.81, 94.63, 77.49, 60.21, 55.88, 55.35, 55.30;
IR (KBr) (vmax/cm
1): 3360, 2926, 1630, 1598, 1546, 1507;
MS (ESI): m/z 559 [M+H]+.
3. Biology
3.1. MTT assay
The cytotoxic activity of the compounds was determined using
MTT assay (Botta et al., 2007) Cells were seeded in 200 lL
DMEM, supplemented with 10% FBS in each well ofPlease cite this article in press as: Sankara Rao, N. et al., Arylcinnamido-propionone
Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.07.01496-well microculture plates and incubated for 24 h at 37 C
in a CO2 incubator. After 24 h of incubation cells were treated
with test compounds 48 h. After 48 h of incubation, 10 ll
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide) (5 mg/ml) was added to each well and the plates were
further incubated for 4 h. Then the supernatant from each well
was carefully removed, formazan crystals were dissolved in
200 lL of DMSO and absorbance at 570 nm wavelength was
recorded.
3.2. Cell cycle analysis
Flow cytometric analysis (FACS) was performed to evaluate
the distribution of the cells through the cell-cycle phases.
DU-145 cells, prostate cancer cells were incubated for 48 h
with compounds 6d and 6g at concentrations of 5 and
10 lM. Untreated and treated cells were harvested, washed
with phosphate-buffered saline (PBS), fixed in ice-cold 70%
ethanol, and stained with propidium iodide (Sigma–Aldrich).
Cell-cycle analysis was performed by flow cytometry (Becton
Dickinson FACS Calibur instrument) (Szumilak et al., 2010).
3.3. Tubulin polymerization assay
A fluorescence based in vitro tubulin polymerization assay was
performed according to the manufacturer’s protocol (BK011,
Cytoskeleton, Inc.). Briefly, the reaction mixture in a total vol-
ume of 10 lL contained PEM buffer, GTP (1 lM) in the pres-
ence or absence of test compounds. Tubulin polymerization
was followed by a time dependent increase in fluorescence
due to the incorporation of a fluorescence reporter into micro-
tubules as polymerization proceeds. Fluorescence emission at
420 nm (excitation wavelength is 360 nm) was measured by
using a Varioskan multimode plate reader (Thermo scientific
Inc.). Cinnamide was used as reference compound in this
study. To determine the IC50 values of the compounds against
tubulin polymerization, the compounds were pre-incubated
with tubulin at varying concentrations. Assay was performed
under similar conditions as employed for polymerization
assays as described above (Huber et al., 2008; Kamal et al.,
2011).
3.4. Mitochondrial membrane potential
DU-145 (1  106 cells/well) cells were cultured in six-well
plates after treatment with compounds 6d and 6g at 5 and
10 lM concentrations for 48 h. After 48 h of treatment, cells
were collected by trypsinization and washed with PBS followed
by resuspending in JC-1 (5 lg/ml) and incubated at 37 C for
15 min. Cells were rinsed three times with medium and sus-
pended in pre warmed medium. The cells were then subjected
to flow cytometric analysis on a flow cytometer (Becton Dick-
inson) in the FL1, FL2 channel to detect mitochondrial poten-
tial (Chakravarti et al., 2012).
3.5. Annexin staining assay for apoptosis
DU-145 (1  106) cells were seeded in six-well plates and
allowed to grow overnight. The medium was then replaced
with complete medium containing compounds 6d and 6g at 5conjugates as tubulin polymerization inhibitors and apoptotic inducers. Arabian
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c O HN
N
H
O
OMe
OMe
OMe
R3
OR4
b
b
b
dd
Scheme 2 Reagents and conditions: (a) (i) (COCl)2, dry DCM, 0 C to rt, 3 h; (ii) Trimethoxy aniline, Et3N, dry THF, 3 h; (b) Zn,
HCO2NH4, MeOH, rt, 6 h; (c) EtOH, 3–4 h; (d) TBAF, dry DCM, 0 C to rt, 3 h; (e) EtOH, 3 h.
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Table 1 Cytotoxicity (IC50 values in lM) of cinnamido-propionone conjugates (4, 5, 6a-h and 7a-f) against a panel of human cancer
cells.a
Compound MCF-7b A549c DU-145d HeLae
4a 10.47 ± 0.91 19.38 ± 0.47 12.88 ± 0.80 9.772 ± 0.59
4b 32.92 ± 1.45 34.29 ± 1.74 12.58 ± 0.78 13.08 ± 0.43
4c 23.88 ± 1.17 28.33 ± 1.21 16.98 ± 0.86 18.75 ± 0.14
4d 14.13 ± 0.51 19.49 ± 0.64 15.84 ± 0.64 17.78 ± 0.91
4f 15.06 ± 0.45 12.84 ± 0.57 9.036 ± 0.58 12.51 ± 1.41
4g 18.46 ± 0.91 21.29 ± 1.13 11.48 ± 0.46 14.27 ± 1.08
4h 14.79 ± 0.32 8.912 ± 0.47 11.74 ± 0.17 13.59 ± 0.98
5a 79.43 ± 7.12 158.4 ± 7.47 45.18 ± 2.85 55.50 ± 3.02
5b 66.06 ± 3.93 77.83 ± 4.66 40.90 ± 2.37 68.71 ± 6.58
5c 70.79 ± 3.58 68.71 ± 4.52 46.00 ± 2.34 61.11 ± 3.54
5d 48.97 ± 2.74 93.32 ± 6.99 40.41 ± 2.69 59.13 ± 2.90
5f 17.51 ± 0.31 21.37 ± 1.02 9.141 ± 0.54 9.931 ± 0.16
5g 14.93 ± 0.91 19.95 ± 1.13 18.55 ± 0.94 9.935 ± 0.88
5h 22.85 ± 1.88 24.50 ± 1.27 12.58 ± 0.41 13.87 ± 0.26
6a 10.71 ± 0.64 22.00 ± 0.66 19.18 ± 1.21 20.07 ± 1.70
6b 125.8 ± 6.12 106.2 ± 5.03 42.20 ± 2.18 44.36 ± 2.38
6c 49.27 ± 2.30 39.50 ± 2.42 17.63 ± 1.31 29.83 ± 1.10
6d 11.48 ± 0.42 12.24 ± 0.61 7.481 ± 0.12 8.128 ± 0.19
6f 14.12 ± 0.77 16.36 ± 0.86 9.332 ± 0.30 13.94 ± 0.75
6g 14.71 ± 0.61 16.14 ± 0.81 8.912 ± 0.15 9.332 ± 0.49
6h 51.87 ± 2.05 58.44 ± 2.96 27.58 ± 1.09 38.28 ± 1.47
7a 16.31 ± 0.91 17.48 ± 0.39 18.72 ± 0.94 5.623 ± 0.28
7b 37.15 ± 0.24 35.77 ± 0.26 10.30 ± 0.74 17.38 ± 0.78
7c 42.75 ± 2.65 63.53 ± 3.20 21.38 ± 0.64 31.17 ± 2.24
7d 158.4 ± 0.65 87.16 ± 1.10 50.11 ± 2.60 93.32 ± 0.02
7f 11.74 ± 0.79 15.51 ± 0.50 24.80 ± 1.23 3.380 ± 0.17
8H 13.48 ± 0.54 9.772 ± 0.49 14.93 ± 0.57 16.93 ± 0.63
a 50% Growth inhibitory concentration and the values are average of three individual experiments after 48 h of drug treatment.
b Breast cancer.
c Lung cancer.
d Prostate cancer.
e Cervical cancer.
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Figure 1 Tubulin polymerization inhibitors.
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Figure 2 Flow cytometric analysis in DU-145 cells after treatment with compounds 6d and 6g. (a) A: Untreated control cells (DU-145),
B: 8H (10 lM), C: 6d (5 lM) and D: 6d (10 lM), E: 6g (5 lM) and F: 6g (10 lM); (b) Bar chart showing the % of cells in different phases
of cell cycle after treatment with compounds 8H, 6d and 6g for 48 h. Values are mean ± S.E. of three experiments. Statistical analysis was
performed using GraphPad Prism software version 5.01 (*p< 0.05 vs control).
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Table 2 Distribution of DU-145 cells in various phases of cell
cycle.
Compounds conc (lM) Distribution (%)
Sub G1% G0/G1% S% G2/M%
A: Control 1.82 95.93 1.36 0.50
B: 8H (10 lM) 0.77 68.41 3.36 28.07
C: 6d (5 lM) 1.25 68.62 3.00 27.85
D: 6d (10 lM) 2.84 47.07 3.62 45.91
E: 6g (5 lM) 1.38 76.56 3.04 19.18
F: 6g (10 lM) 1.00 64.43 4.39 30.52
Table 3 Inhibition of tubulin polymerization (IC50) of com-
pounds 6d, 6g and 8H.
Compound IC50
a ± SD (in lM)
6d 8.98 ± 0.31
6g 9.57 ± 0.12
8H 10.11 ± 0.64
Nocodazole 2.09 ± 0.52
a Concentration of drug to inhibit 50% of tubulin assembly.
12 N. Sankara Rao et al.and 10 lM concentrations. After 48 h of drug treatment, cells
from the supernatant and adherent monolayer cells were har-
vested by trypsinization and washed with PBS at 5000 rpm.
Then the cells were stained with Annexin VFITC and propid-
ium iodide using the Annexin-V-FITC apoptosis detection kit
(Sigma Aldrich). Flow cytometry was performed for this study
as described earlier (Browne et al., 1991).
4. Results and discussions
4.1. Chemistry
Synthetic strategies for the preparation of cinnamido-
propionone conjugates are depicted in Schemes 1 and 2. Ini-
tially, substituted nitro cinnamic acids (8a, 8b and 14a, 14b)
were converted into their corresponding acid chlorides by
reacting with oxaloyl chloride in dry CH2Cl2 at 0 C for 3 h.
These corresponding acid chlorides were then coupled with tri-
methoxy aniline in triethylamine as a base at 0 C for 3 h to
afford the corresponding nitro cinnamide derivatives (9a, 9b
and 15a, 15b) in excellent yields (83–89%). These nitro cin-
namides are reduced by using zinc ammonium formate in
methanol to obtain the amine derivatives (10a, 10b and 16a,
16b). The substituted phenylpropynones 13a–e that are
required as another precursor were obtained by the reaction
of aldehydes (11a-e) upon treatment with ethynyl magnesium
bromide (0.5 M) in THF (0 C to room temperature) forFigure 3 Effect of conjugates on tubulin polymerization: tubulin p
360 nm (excitation) and 420 nm (emission) for 1 h at 37 C. Values ind
in triplicate (*p< 0.05 vs control).
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12a-e with 2-iodoxybenzoic acid (IBX) in dimethyl sulfoxide
(DMSO) gave the substituted phenylpropynones (13a-e). The
synthesis of the desired cinnamido-propionone conjugates
(4a-h and 7a-f) was carried out by exposing alkynes to the cin-
namides in ethanol for 3 h to afford them in good yields, and
their structures were confirmed by 1H and 13C NMR, HRMS,
and IR spectral analysis.
4.2. Biology
4.2.1. Cytotoxic activity
Preliminary screening of the synthesized conjugates (4–6a-h
and 7a-f) was performed to evaluate their cytotoxic potential
against a panel of selected human cancer cell lines like MCF-
7 (breast), A549 (lung) DU-145 (prostate) and HeLa (cervical)
by using MTT assay (Vichai and Kirtikara, 2006) as shown in
Table 1. Among the series, compounds 6d and 6g showed sig-
nificant cytotoxic activity against human prostate cancer cell
line (DU-145), as such this cell line was chosen for subsequent
studies.
The results of this cytotoxicity data expressed as IC50 values
in comparison with 8H are summarized in Table 1. Interest-
ingly, these conjugates showed considerable cytotoxic activity
against most of the cell lines with micromolar range. Among
the series, compounds 6d and 6g showed significant cytotoxic
activity than 8H against human prostate cancer cell line
(DU-145), as such this cell line was chosen for subsequent
studies such as inhibition of tubulin polymerization as well
as apoptosis induction (see Fig. 1).olymerization was monitored by the increase in fluorescence at
icated are the mean ± SD of two different experiments performed
conjugates as tubulin polymerization inhibitors and apoptotic inducers. Arabian
Figure 4 Compounds 6d, 6g and 8H trigger mitochondrial injury. Drops in membrane potential (DWm) were assessed by JC-1 staining of
DU-145 cells treated with test compound and samples were then subjected to flow cytometry analysis on a FACScan (Becton Dickinson)
in the FL1, FL2 channel to detect mitochondrial potential. (a) A: Untreated control cells (DU-145), B: Cinnamide (10 lM), C: 6d (5 lM)
and D: 6d (10 lM), E: 6g (5 lM) and F: 6g (10 lM); (b) Bar chart showing the ratio of red/green fluorescence. Values are mean ± S.E. of
three experiments. Statistical analysis was performed using GraphPad Prism software version 5.01 (*p< 0.05 vs control).
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Figure 5 Annexin V-FITC staining. (a) A: Untreated control cells (DU-145), B: 8H (10 lM), C: 6d (5 lM) and D: 6d (10 lM), E: 6g
(5 lM) and F: 6g (10 lM); (b) Bar chart showing the % of apoptosis in DU-145 cells after treatment with compounds 8H, 6d and 6g for
48h. Values are mean ± S.E. of three experiments. Statistical analysis was performed using GraphPad Prism software version 5.01
(*p< 0.05 vs control).
14 N. Sankara Rao et al.4.2.2. Cell cycle analysis
Many anticancer compounds exert their growth inhibitory
effect either by arresting the cell cycle at a particular check-
point of the cell cycle or by induction of apoptosis or a com-Please cite this article in press as: Sankara Rao, N. et al., Arylcinnamido-propionone
Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.07.014bined effect of both cycle block and apoptosis (Chan et al.,
2010; Shen et al., 2009). The in vitro screening results revealed
that compounds 6d and 6g showed significant cytotoxic activ-
ity against human prostate cancer cell line (DU-145). There-conjugates as tubulin polymerization inhibitors and apoptotic inducers. Arabian
Table 4 Distribution of apoptotic cells in Annexin-V FITC experiment.
Sample UL% UR% LL% LR%
A: Control 0.38 1.60 97.60 0.41
B: 8H(10 lM) 3.34 17.68 74.06 4.92
C: 6d (5 lM) 2.87 14.67 78.93 3.52
D: 6d (10 lM) 3.04 22.82 69.63 4.22
E: 6g (5 lM) 2.51 13.00 80.37 4.13
F: 6g (10 lM) 3.34 21.31 71.04 4.30
Figure 6 Superposition of binding modes of 6d and 6g (A and B) into colchicine binding site along with the standard 8H (C).
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inhibition of cell growth was on account of cell cycle arrest.
In this study DU-145 cells were treated with these compounds
at 5 and 10 lM concentrations for 48 h, and the data obtained
clearly indicated that these compounds arrested the cell cycle
at G2/M phase as shown in Fig. 2 and Table 2.
4.2.3. Effect on tubulin polymerization
In general G2/M cell cycle arrest is strongly associated with the
inhibition of tubulin polymerization (Kanthou et al., 2004) and
since conjugates 6d and 6g cause cell cycle arrest at G2/M
phase, it was considered of interest to investigate their micro-
tubule inhibitory function. Tubulin subunits are known to
heterodimerize and self-assemble to form microtubules in a
time dependent manner. The progression of tubulin polymer-
ization was thus examined by monitoring the increase in fluo-
rescence emission at 420 nm at 5 lM concentration (excitation
wavelength is 360 nm) in 384 well plate for 1 h at 37 C with
and without the conjugates 6d, 6g 8H, and nocodazole. These
conjugates significantly inhibited tubulin polymerization by
56.13, 53.74 and 50.72% and 68.92% respectively as seen from
Fig. 3. This was followed by the evaluation of IC50 values for
these conjugates and the results are shown in Table 3. It is
observed that these conjugates 6d, 6g and 8H, nocodazole
showed tubulin-assembly inhibition with IC50 values of 8.98,
9.57 and 10.11, 2.09 lM respectively.
4.2.4. Measurement of mitochondrial membrane potential
(DWm)
The maintenance of mitochondrial membrane potential (DWm)
is significant for mitochondrial integrity and bioenergetic func-
tion (Gonda et al., 2008). Mitochondrial changes, including
loss of mitochondrial membrane potential (DWm), are key
events that take place during drug-induced apoptosis. Mito-Please cite this article in press as: Sankara Rao, N. et al., Arylcinnamido-propionone
Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.07.014chondrial injury by 6d, 6g and 8H was evaluated by detecting
drop in mitochondrial membrane potential (DWm). In this
study we have investigated the involvement of mitochondria
in the induction of apoptosis by these conjugates. After 48 h
of drug treatment with these conjugates, it was observed that
the mitochondrial membrane potential (DWm) of DU-145 cells
reduced as assessed by JC-1 staining (Fig. 4).
4.2.5. Annexin V-FITC for apoptosis
The apoptotic effect of 6d and 6g in comparison to 8H was fur-
ther evaluated by Annexin V FITC/PI (AV/PI) dual staining
assay to examine the occurrence of phosphatidylserine exter-
nalization and also to understand whether it is due to physio-
logical apoptosis or nonspecific necrosis (Zhu et al., 2010). In
this study DU-145 cells were treated with these conjugates for
48 h at 5 and 10 lM concentrations to examine the apoptotic
effect. It was observed that these conjugates showed significant
apoptosis against DU-145 cells as shown in Fig. 5. Results
indicated that conjugates 6d and 6g showed 18.19 and
17.13% of apoptosis at 5 lM concentration, whereas they
exhibited 27.04 and 25.61% of apoptosis at 10 lM concentra-
tion respectively for 48 h, whereas 8H showed 22.6% apoptosis
at 10 lM concentration when compared to untreated control
cells as shown in Table 4.
4.2.6. Molecular modelling studies: (Cormier et al., 2008)
We know that cinnamides are often key pharmacophores
prevalent in many anticancer leads which act through inhibit-
ing tubulin polymerization. Moreover, this has been experi-
mentally proven which is discussed in the previous sections.
Therefore, molecular docking studies were performed to get
an insight into binding modes of the promising conjugates 6d
and 6g with the tubulin. The coordinates of the protein struc-
ture cocrystallized with colchicine (PDB ID: 3E22) (Cormierconjugates as tubulin polymerization inhibitors and apoptotic inducers. Arabian
16 N. Sankara Rao et al.et al., 2008) were obtained from Protein Data Bank. Docking
studies were performed using AutoDock 4.2 (Morris et al.,
2009) and the visualization was done using Pymol, v. 0.99
(Delano, 2002). Docking pose shown in Fig. 6 indicates that
the trimethoxy phenyl ring of the cinnamide moiety in both
6d and 6g was buried in the hydrophobic region of the colchi-
cine binding site in the b chain, similar to that of colchicine.
Both the compounds were found to interact extensively with
the neighbouring amino acid residues such as Val 238, Cys
241, Leu 248, Asn 249, Ala 250, Leu 255, Val 318, Ileu 378
and Ala 354. Interestingly, 6d and 6g displayed several hydro-
gen bonding interactions with the amino acid residues in prox-
imity that include Thr 179, Asn 101, Lys 254, Ala 317 and Tyr
202, Ala 250, Lys 254, Asn 249 respectively. It is important to
note that these amino acid residues form hydrogen bond with
all the major functionalities and rings contained in 6d and 6g.
Besides this both the compounds established a series of sec-
ondary interactions such as van der Waal and polar interac-
tions with some other amino acid residues. On the other
hand, the standard 8H was found to establish only two hydro-
gen bonds with Tyr 224 in addition to some hydrophobic and
polar interactions with the surrounding amino acid residues.
The different binding modes of 6d and 6g than 8H may be
due to the longer keto-enamine substitution on the cinnamide
pharmacophore. Therefore, this study infers that compounds
6d and 6g bind to the colchicine binding pocket of tubulin bet-
ter than the standard which is in correlation with the cytotox-
icity data represented in Table 1.
5. Conclusion
In the present study, we have synthesized cinnamido-propionone con-
jugates and evaluated them for their cytotoxic potential. Among them,
conjugates 6d and 6g showed significant cytotoxic activity against
human prostate cancer cell line, (DU-145). The flow cytometric analy-
sis revealed that these conjugates cause cell cycle arrest at G2/M phase.
Furthermore, they effectively inhibited microtubule assembly. More-
over, the triggering of the apoptotic cell death after mitotic arrest
was investigated by mitochondrial membrane potential and Annexin
V FITC assays suggested that these conjugates induced apoptosis.
The molecular modelling study carried out on the colchicine binding
site of tubulin demonstrated that these molecules are involved in a ser-
ies of interactions with the protein thereby binding well with the tubu-
lin. Therefore, the work reported herein could be considered of
significant importance to provide valuable insights in the development
of newer leads for the treatment of cancer.
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